Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Selected Treatment Schedules: Cholangiocarcinoma, Hepatocellular Carcinoma

Selected Treatment Schedules

2dd, twice daily; AUC, area under the concentration–time curve; BMI, body mass index; FU, fluorouracil; HER2, human epidermal growth factor receptor 2; FOLFIRI, folinic acid, fluorouracil and irinotecan; 5-FU, 5-fluorouracil.

Cholangiocarcinoma

(Neo)adjuvant	Palliative
---	GemCis: 3-weekly gemcitabine 1000 mg/m² d1 and 8, cisplatin 25 mg/m² d1 and 8^[32]

References

32. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362:1273–1281.

Hepatocellular carcinoma

(Neo)adjuvant	Palliative
---	Sorafenib 2dd 400 mg^[33]

References

33. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378–390.